NCT03556345View on ClinicalTrials.gov

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

June 1, 2020

Study Completion Date

August 31, 2020

Conditions
Gastric CancerHER2 Overexpressing Gastric Carcinoma
Interventions
DRUG

RC48-ADC

2.5 mg/kg IV every 2 weeks

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT03556345 - A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 | Biotech Hunter | Biotech Hunter